Earticle

초록

영어

Background: The indication of denosumab for osteoporosis was expanded from second-line to first-line therapy in 2019. The aim of this study was to evaluate the efficacy of denosumab as both first- and second-line therapy in postmenopausal women with osteoporosis and osteopenia with risk factors by using the Fracture Risk Assessment Tool (FRAX). Methods: We conducted a medication use evaluation of denosumab in 98 patients who had been treated three or more times for osteoporosis or osteopenia at Chungnam National University Hospital from July 1st, 2017 to January 31st, 2020. Risk factors were identified using quantitative Ngram analyses of FRAX estimations. Patient information, including menopause status and results of bone mineral density tests (Tscore), was obtained from electronic medical records. Results: Age, body mass index (BMI), prior medication use, and T-score were identified as risk factors and were included as variables in the evaluation of denosumab use. Since no significant differences were detected between groups, denosumab is likely effective regardless of age or BMI. In addition, no significant difference was detected in T-scores following denosumab treatment, between groups who took bisphosphonates and selective estrogen receptor modulators (SERMs) with denosumab as first-line therapy for postmenopausal osteoporosis. Denosumab may, therefore, be effective as second-line therapy. Conclusion: Efficacy of denosumab was evaluated in postmenopausal women with osteoporosis. Denosumab may be used as first- and second-line therapy regardless of age, BMI, and prior use of bisphosphonates and SERMs.

목차

ABSTRACT
연구 방법
연구대상선정
자연어 분석을 통한 생체표지자 설정 및 자료 수집
Denosumab 약물 사용 평가
통계분석
연구 결과
연구대상 특성
생체표지자 분석을 위한 자연 언어 분석 결과
연령별 denosumab 투여 전후 T-score 변화 분석
체질량지수별 denosumab 투여 전후 T-score 변화 분석
Denosumab 치료 시작 전 골다공증 타 치료제 효과 비교
연령 및 체질량지수별 denosumab 시작 1년 내 치료효과 비교
Denosumab 5회 투여 환자군의 T-score 변화 비교
결론 및 고찰
감사의 말씀
이해상충
참고문헌

키워드

저자

• 임선혜 [ Seon-Hye Lim | 충남대학교병원 약제부, 충남대학교 약학대학 ]
• 정우진 [ Woo Jin Jung | 충남대학교 약학대학 ]
• 채정우 [ Jung-woo Chae | 충남대학교 약학대학 ] Co-Correspondence to
• 강찬 [ Chan Kang | 충남대학교병원 정형외과, 충남대학교 의과대학 ] Co-Correspondence to
• 윤휘열 [ Hwi-yeol Yun | 충남대학교 약학대학 ] Correspondence to

참고문헌

발행기관

간행물

표지보기 관심저널 등록

• 간행물명

  한국임상약학회지 [Korean Journal of Clinical Pharmacy]

• 간기

  계간

• pISSN

  1226-6051

• 수록기간

  1991~2026

• 등재여부

  KCI 등재

• 십진분류

  KDC 518 DDC 615